SHANG.FOS.PHARM.GR.H YC 1 Cash Flow-to-Debt Ratio
SHANG.FOS.PHARM.GR.H YC 1 cash flow-to-debt ratio. SHANG.FOS.PHARM.GR.H YC 1 (08HH) has a Cash Flow-to-Debt Ratio of 0.09x as of December 2025, meaning its operating cash flow of €5.21 Billion could theoretically repay 0% of its total liabilities (€58.21 Billion) in one year. Check earnings quality score of SHANG.FOS.PHARM.GR.H YC 1 to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
Cash flow-to-debt ratio of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025. Historical debt coverage capacity for SHANG.FOS.PHARM.GR.H YC 1 across 5 annual periods. Check SHANG.FOS.PHARM.GR.H YC 1 (08HH) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
SHANG.FOS.PHARM.GR.H YC 1 Cash Flow-to-Debt Ratio by Year (2021–2025)
SHANG.FOS.PHARM.GR.H YC 1 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for SHANG.FOS.PHARM.GR.H YC 1. For the full cash flow conversion analysis, see 08HH cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | €5.21 Billion | €58.21 Billion | ▲ +15.1% |
| 2024 | 0.08x | €4.48 Billion | €57.53 Billion | ▲ +29.6% |
| 2023 | 0.06x | €3.41 Billion | €56.85 Billion | ▼ -24.5% |
| 2022 | 0.08x | €4.22 Billion | €53.05 Billion | ▼ -9.3% |
| 2021 | 0.09x | €3.94 Billion | €44.93 Billion | — |